Download PDF
Fortschr Neurol Psychiatr 2010; 78(3): 169-183
DOI: 10.1055/s-0028-1109692
Fort- und Weiterbildung

© Georg Thieme Verlag KG Stuttgart · New York

Therapieresistente Depressionen

Teil II: Psychopharmakologische Behandlungsstrategien, Hirnstimulations- und andere somatische TherapieverfahrenTreatment-Resistant DepressionPart II: Psychopharmacological Treatment, Strategies, Brain Stimulation and Other Somatic TreatmentoptionsM. Schmauß1 , T. Messer1
  • 1Bezirkskrankenhaus Augsburg
Further Information

Publication History

Publication Date:
07 September 2009 (online)

    Permissions and Reprints

Lernziele

Kenntnis über

wichtige psychopharmakologische Behandlungsstrategien (Hochdosierung, Switching, Kombinationstherapien, Augmentationstherapien) bei therapieresistenten Depressionen Hirnstimulationsverfahren (EKT, rTMS, VNS) Schlafentzugs- und Lichttherapie

Literatur

  • 1 Möller H J. Therapieresistenz auf Antidepressiva.  Nervenarzt. 2004;  75 499-517
    Google Scholar
  • 2 Möller H J. Medikamentöse Therapiestrategien bei therapieresistenter unipolarer Depression.  Psychopharmakotherapie. 2004;  11 34-41
    Google Scholar
  • 3 Souery D, Papakostas G I, Trivedi M H. Treatment-resistant depression.  J Clin Psychiatry. 2006;  67 (Suppl 6) 16-22
    Google Scholar
  • 4 Adli M, Baethge C, Heinz A. et al . Is dose escalation of antidepressants a rational strategy after a medium-dose treatment has failed? A systematic review.  Eur Arch Psychiatry Clin Neurosci. 2005;  255 387-400
    Google Scholar
  • 5 Harrison C L, Ferrier N, Young A H. Tolerability of high-dose venlafaxine in depressed patients.  J Psychopharmacol. 2004;  18 200-204
    Google Scholar
  • 6 Thase M E, Shelton R C, Khan A. Treatment with venlafaxine extended release after SSRI nonresponse or intolerance: a randomized comparison of standard- and higher-dosing strategies.  J Clin Psychopharmacol. 2006;  26 250-258
    Google Scholar
  • 7 Thase M E, Rush A J. When at first you don’t succeed: sequential strategies for antidepressant nonresponsers.  J Clin Psychiatry. 1997;  58 (Suppl 1) 23-29
    Google Scholar
  • 8 Thase M E, Feighner J P, Lydiard R B. Citalopram treatment of fluoxetine nonresponders.  J Clin Psychiatry. 2001;  62 683-687
    Google Scholar
  • 9 Fava M, McGrath P J, Sheu W P. et al . Switching fluoxetine to reboxetine: an efficacy and safety study in depressed patients resistant to fluoxetine (abstract p03.198).  Int J Neuropsychopharmacol. 2000;  3 234
    Google Scholar
  • 10 Thase M E, Rush A J. Treatment-resistant depression. Bloom FE, Kupfer DJ Psychopharmacology: the fourth generation of progress New York; Raven Press 1995: 1081-1097
    Google Scholar
  • 11 AHCPR .Depression Guidelines Panel-Depression in primary care: Clinical practice guideline no. 5 AHCPR pub No 93 – 0550,. Rockville MD 1993
    Google Scholar
  • 12 Rush A J, Trivedi M H, Wisniewski S R. et al . Bupropion-SR, sertraline, or venlafaxine-XR after failure of SSRIs for depression.  N Engl J Med. 2006;  354 1231-1242
    Google Scholar
  • 13 Taylor D, Stewart S, Connolly A. Antidepressant withdrawal symptoms-telephone calls to a national medication helpline.  J Affect Disord. 2006;  95 129-133
    Google Scholar
  • 14 Dodd S, Horgan D, Malhi G. et al . To combine or not to combine? A literature review of antidepressant combination therapy.  J Affect Disord. 2005;  89 1-11
    Google Scholar
  • 15 Schmauß M, Messer T. Kombination von Antidepressiva – eine sinnvolle Behandlungsstrategie bei therapieresistenten Depressionen?.  Fortschr Neurol Psychiat. 2009;  77 316-325
    Google Scholar
  • 16 Schmauß M, Messer T. Polypharmazie in der Behandlung depressiver Störungen. Messer T, Schmauß M Polypharmazie in der Behandlung psychischer Erkrankungen Wien, New York; Springer 2009; im Druck 2. Aufl
    Google Scholar
  • 17 Bauer M, Linden M. Die Kombination verschiedener Antidepressiva in der Behandlung therapieresistenter Depressionen.  Nervenarzt. 1993;  64 343-347
    Google Scholar
  • 18 Frye M A, Ketter T A, Leverich G S. et al . The increasing use of polypharmacotherapy for refractory mood disorders: 22 years of study.  J Clin Psychiatry. 2000;  61 9-15
    Google Scholar
  • 19 Murphy D L, Sunderland T, Cohen R M. Monoamine oxidase-inhibiting antidepressants – a clinical update.  Psychiatr Clin North Am. 1984;  7 549-562
    Google Scholar
  • 20 Schuckit M, Robins E, Feighner J. Tricyclic antidepressants and monoamine oxidase inhibitors.  Arch Gen Psychiatry. 1971;  24 509-514
    Google Scholar
  • 21 Schmauß M. Kombinationstherapie nicht-selektiver Monoamin-Rückaufnahme-Inhibitoren mit MAO-Hemmern. Riederer P, Laux G, Pöldinger W Neuro-Psychopharmaka. Bd 3: Antidepressiva Phasenprophylaktika und Stimmungsstabilisierer, Wien, New York; 2002 2. Aufl: 551-557
    Google Scholar
  • 22 Steinberg R, Jost C, Weess H G. et al . Combination of tricyclic antidepressants with moclobemide or tranylcypromine – outcome data in therapy resistant MD.  Neuropsychopharmacology (Suppl). 1994;  10 62
    Google Scholar
  • 23 Koenig F, Wolfersdorf M. Combination therapy using moclobemide with tricyclic and tetracyclic antidepressants to treat therapy-resistant depression.  Pharmacopsychiatry. 1997;  30 93-96
    Google Scholar
  • 24 Neuvonen P, Pohjola-Sintonen S, Tacke U. et al . Five fatal cases of serotonin syndrome after moclobemide-citalopram or moclobemide-clomipramine overdoses.  Lancet. 1993;  342 1419
    Google Scholar
  • 25 Hawley C J, Quick S J, Ratnam S. Safety and tolerability of combined treatment with moclobemide and SSRI: a systematic study of 50 patients.  Int Clin Psychopharmacol. 1996;  11 187-191
    Google Scholar
  • 26 Dams R, Benijts T H, Lambert W E. et al . A fatal case of serotonin syndrome after combined moclobemide-citalopram intoxication.  J Anal Toxicol. 2001;  25 147-151
    Google Scholar
  • 27 Volz H P, Gleiter C H, Möller H J. Monoaminoxidasehemmer in der Psychiatrie.  Nervenarzt. 1996;  67 339-347
    Google Scholar
  • 28 Baron B M, Ogden A, Seigel B W. et al . Rapid down regulation of β-adrenoreceptors by co-administration of desipramine and fluoxetine.  Eur J Pharmacol. 1988;  154 125-134
    Google Scholar
  • 29 Nelson J C. Augmentation strategies with serotonin-noradrenergic combinations.  J Clin Psychiatry. 1998;  59 65-68
    Google Scholar
  • 30 Nelson J C, Mazure C M, Browers M BJ. et al . A preliminary, open study of the combination of fluoxetine and desipramine for rapid treatment of major depression.  Arch Gen Psychiatry. 1991;  48 303-307
    Google Scholar
  • 31 Dam J, Ryde L, Svejso J. et al . Morning fluoxetine plus evening mianserin versus morning fluoxetine plus evening placebo in the acute treatment of major depression.  Pharmacopsychiatry. 1998;  31 48-54
    Google Scholar
  • 32 Ferreri M, Lavergne F, Berlin I. et al . Benefits from mianserin augmentation of fluoxetine in patients with major depression non-responders to fluoxetine alone.  Acta Psychiatr Scand. 2001;  103 66-72
    Google Scholar
  • 33 Maes M, Vandoolaeghe E, Desnyder R. Efficacy of treatment with trazodone in combination with pindolol or fluoxetine in major depression.  J Affect Disord. 1996;  41 201-210
    Google Scholar
  • 34 Harkin A, Kelly J P, McNamara M. et al . Activity and onset of action of reboxetine and effect of combination with sertraline in an animal model of depression.  Eur J Pharmacol. 1999;  364 123-132
    Google Scholar
  • 35 Carpenter L L, Yasmin S, Price H. A double-blind, placebo-controlled study of antidepressant augmentation with mirtazapine.  Biol Psychiatry. 2002;  51 183-188
    Google Scholar
  • 36 Debonnel G, Gobbi G, Turcotte J. et al .The alpha-2 antagonist mirtazapine combined with the SSRI paroxetine induces a greater antidepressant response: a double-blind controlled study. Presented at the 39th ACNP Meeting, Dec 10 – 14, San Juan, Puerto Rico, 2002. 
    Google Scholar
  • 37 Farah A. Relief of SSRI-induced sexual dysfunction with mirtazapine treatment (letter).  J Clin Psychiatry. 1999;  60 260-261
    Google Scholar
  • 38 McGrath P J, Stewart J W, Fava M. et al . Tranylcypromine versus venlafaxine plus mirtazapine following three failed antidepressant medication trials for depression: a Star*D report.  Am J Psychiatry. 2006;  163 1531-1541
    Google Scholar
  • 39 Lam R W, Hossie H, Solomons K. et al . Citalopram and bupropion SR: combining vs. switching in patients with treatment-resistant depression.  J Clin Psychiatry. 2004;  65 337-340
    Google Scholar
  • 40 Papakostas G I, Worthington J J, Iosifescu D V. et al . The combination of duloxetine and bupropion for treatment-resistant major depressive disorder.  Depress Anxiety. 2006;  3 178-181
    Google Scholar
  • 41 DeBattista C, Solvason H B, Poirier J. et al . A prospective trial of bupropion SR augmentation of partial and non-responsers to serotonergic antidepressants.  J Clin Psychopharmacol. 2003;  23 27-30
    Google Scholar
  • 42 Zisook S, Rush A J, Haight B R. et al . Use of bupropion in combination with serotonin reuptake inhibitors.  Biol Psychiatry. 2006;  59 203-210
    Google Scholar
  • 43 Trivedi M H, Fava M, Wisniewski S R. et al . Medication augmentation after the failure of SSRIs for depression.  N Engl J Med. 2006;  12 1243-1252
    Google Scholar
  • 44 Lam R W, Wan D D, Cohen N L. et al . Combining antidepressants for treatment-resistant depression. A review.  J Clin Psychiatry. 2002;  63 685-693
    Google Scholar
  • 45 Bauer M, Whybrow P C. Thyroid hormone, neural tissue and mood modulation.  World J Biol Psychiatry. 2001;  2 57-67
    Google Scholar
  • 46 Baumgartner A. Schilddrüsenhormone und depressive Erkrankungen. Teil I.  Nervenarzt. 1993;  64 1-10
    Google Scholar
  • 47 Crossley N A, Bauer M. Acceleration and augmentation of antidepressants with lithium for depressive disorders: two meta-analysis of randomized, placebo-controlled trials.  J Clin Psychiatry. 2007;  68 935-940
    Google Scholar
  • 48 Bauer M, Forsthoff A, Baethge C. et al . Lithium augmentation therapy in refractory depression – update 2002.  Eur Arch Psychiatry Clin Neurosci. 2003;  253 132-139
    Google Scholar
  • 49 Zullino D, Baumann P. Lithium augmentation in depressive patients not responding to selective serotonin reuptake inhibitors.  Pharmacopsychiatry. 2001;  34 119-127
    Google Scholar
  • 50 Shelton R C, Papakostas G I. Augmentation of antidepressants with atypical antipsychotics for treatment-resistant major depressive disorder.  Acta Psychiatr Scand. 2008;  117 253-259
    Google Scholar
  • 51 Shelton R C, Williamson D J, Corya S A. et al . Olanzapine/fluoxetine combination for treatment-resistant depression: a controlled study of SSRI and nortriptyline resistance.  J Clin Psychiatry. 2005;  66 1289-1297
    Google Scholar
  • 52 Corya S A, Williamson D, Sanger T M. et al . A randomized, double-blind comparison of olanzapine/fluoxetine combination, olanzapine, fluoxetine, and venlafaxine in treatment-resistant depression.  Depression and Anxiety. 2006;  23 364-372
    Google Scholar
  • 53 Papakostas G I, Shelton R C, Smith J. et al . Augmentation of antidepressants with atypical antipsychotic medications for treatment-resistant major depressive disorder: a meta-analysis.  J Clin Psychiatry. 2007;  68 826-831
    Google Scholar
  • 54 Warneke L. Psychostimulants in psychiatry.  Can J Psychiatry. 1990;  35 3-10
    Google Scholar
  • 55 Robertson Jr P, Hellriegel E T. Clinical pharmacokinetic profile of modafinil.  Clin Pharmacokinet. 2003;  42 123-137
    Google Scholar
  • 56 Ninan P T, Hassman H A, Glass S J. et al . Adjunctive modafinil at initiation of treatment with a selective serotonin reuptake inhibitor enhances the degree and onset of therapeutic effects in patients with major depressive disorder and fatigue.  J Clin Psychiatry. 2004;  65 414-420
    Google Scholar
  • 57 Landen M, Bjorling G, Agren H. et al . A randomized, double-blind, placebocontrolled trial of buspirone in combination with an SSRI in patients with treatment refractory depression.  J Clin Psychiatry. 1998;  59 664-668
    Google Scholar
  • 58 Sachs G, Collins M A, Altshuler L. et al .Divalproax sodium versus placebo for the treatment of bipolar depression. APA 2002 Syllabus & Proceedings Summary Washington DC 2002
    Google Scholar
  • 59 Barbee J G, Jamhour N J. Lamotrigine as an augmentation agent in treatment-resistant depression.  J Clin Psychiatry. 2002;  63 (Suppl 8) 737-741
    Google Scholar
  • 60 Dietrich D E, Emrich H M. The use of anticonvulsants to augment antidepressant medication.  J Clin Psychiatry. 1998;  59 (Suppl 5) 51-58
    Google Scholar
  • 61 Cassano P, Lattanzi L, Fava M. et al . Ropinirole in treatment-resistant depression: a 16-week pilot study.  Can J Psychiatry. 2005;  50 357-360
    Google Scholar
  • 62 Dawson L A, Nguyen H Q. The role of 5-HAT(1A) and 5-HAT(1B/ 1D) receptors on the modulation of acute fluoxetine-induced changes in extracellular 5-HAT: the mechanism of action of (+ /–) pindolol.  Neuropharmacology. 2000;  39 1044-1052
    Google Scholar
  • 63 Olver J S, Cryan J F, Burrows G D. et al . Pindolol augmentation of antidepressants: a review and rationale.  Aust N Z J Psychiatry. 2000;  34 71-79
    Google Scholar
  • 64 Erfurth A, Möller H J. Vorgehen bei Antidepressiva-Nonrespondern. Möller HJ Therapie psychiatrischer Erkrankungen Stuttgart, New York; Thieme 2000 2. Aufl: 407-412
    Google Scholar
  • 65 Abrams R. Electroconvulsive Therapy. Oxford, New York; Oxford University Press 2002
    Google Scholar
  • 66 Pagnin D, Queiroz de V, Pini S. et al . Efficacy of ECT in depression: a meta-analytic review.  J ECT. 2004;  20 13-20
    Google Scholar
  • 67 American Psychiatric Association (APA) . Practice guideline for the treatment of patients with major depressive disorder (revision).  Am J Psychiatry. 2000;  157 1-45
    Google Scholar
  • 68 National Institute for Clinical Excellence .Depression: Management of depression in primary and secondary care. Clinical Guidelines 2004 23 http://www.nice.org.uk/CGO23 NICEguideline
    Google Scholar
  • 69 UK ECT Review-Group . Efficacy and safety of electroconvulsive therapy in depressive disorders: a systematic review and meta-analysis.  Lancet. 2003;  361 799-808
    Google Scholar
  • 70 Bourgon L N, Kellner C H. Relapse of depression after ECT: a review.  J ECT. 2000;  16 19-31
    Google Scholar
  • 71 O’Reardon J P, Solvason H B, Janicak P G. et al . Efficacy and safety of transcranial magnetic stimulation in the acute treatment of major depression: a multisite randomized controlled trial.  Biol Psychiatry. 2007;  62 1208-1216
    Google Scholar
  • 72 Rush A J, George M S, Sackeim H A. et al . Vagus nerve stimulation (VNS) for treatment-resistant depressions: a multicenter study.  Biol Psychiatry. 2000;  47 276-286
    Google Scholar
  • 73 Kuhn J, Huff W, Lee S H. et al . Tiefenhirnstimulation bei psychiatrischen Erkrankungen.  Fortschr Neurol Psychiat. 2007;  75 447-457
    Google Scholar
  • 74 Golden R N, Gaynes B N, Ekstrom R D. et al . The efficacy of light therapy in the treatment of mood disorders. A review and meta-analysis of the evidence.  Am J Psychiatry. 2005;  62 656-662
    Google Scholar
  • 75 Kennedy S H, Lam R W, Cohen N L. et al . Clinical guidelines for the treatment of depressive disorders. IV: Medications and other biological treatments.  Can J Psychiatry. 2001;  46 38-58
    Google Scholar
  • 76 Rush A J. Aktueller Stand und Perspektiven der Forschung. Bauer M, Berghöfer A, Adli M Akute und therapieresistente Depressionen Heidelberg; Springer 2005 2. Aufl: 3-19
    Google Scholar
  • 77 Adli M, Rush A J, Möller H J. Algorithms for optimizing the treatment of depression: making the right decision at the right time.  Pharmacopsychiatry. 2003;  36 222-229
    Google Scholar
  • 78 Adli M, Bauer M, Rush A J. Algorithms and collaborative-care systems for depression: are they effective and why? A systematic review.  Biol Psychiatry. 2006;  59 1029-1038
    Google Scholar
  • 79 Trivedi M H, Rush A J, Crismon M L. et al . Texas Medication Algorithm Project (TMAP): Clinical results for patients with major depressive disorder.  Arch Gen Psychiatry. 2004;  61 669-680
    Google Scholar
  • 80 DGPPN .S3-Leitlinie zur Behandlung depressiver Störungen. Darmstadt; Steinkopff 2009; im Druck
    Google Scholar
  • 81 Canadian Psychiatric Association . Clinical guidelines for the treatment of depressive disorders.  Can J Psychiatry. 2001;  46 (Suppl 1) 13-90
    Google Scholar
  • 82 Menke R, Gaebel W. Leitlinienkonformität in Klinik und Praxis.  Psychopharmakotherapie. 2005;  12 (Suppl 13) 3-7
    Google Scholar
  • 83 Bauer M, Whybrow P C, Angst J. et al .Biologische Behandlung unipolarer depressiver Störungen, Behandlungsleitlinien der World Federation of Societies of Biological Psychiatry (WFSBP). Stuttgart; Wissenschaftliche Verlagsgesellschaft 2004
    Google Scholar

Prof. Dr. med. M. Schmauß

Ärztlicher Direktor, Bezirkskrankenhaus Augsburg

Dr.-Mack-Straße 1

86156 Augsburg

Email: m.schmauss@bkh-augsburg.de

      >